Daxor Corporation · NASDAQ:DXR
Daxor — Investor Presentation (May 2023)
42 slides from Daxor's investor presentation, May 2023
Slide 1: Corporate Presentation May 2023
Corporate Presentation May 2023 Nasdaq: DXR
Slide 2: Forward-Looking Statement
Forward-Looking Statement Certain statements in this presentation may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution c
Slide 3: COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 4: Daxor is the global leader in blood volume measurement technology
owns and operates a 20,000 SF Daxor is the global leader in blood volume state-of-the-art production and R&D facility in Oak Ridge, TN measurement technology focused on blood volume testing innovation. COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 5: Optimal Blood Volume Management Is Key to Improving Outcomes
Optimal Blood Volume Management Is Key to Improving Outcomes ~130M Patients U.S. Healthcare Burden Heart Failure $30+ Billion Hypertension $48.6+ Billion Critical Care $121-263 Billion COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 6: Managing Volume Derangement is a Challenge for Both Inpatient & Outpatient Care
Managing Volume Derangement is a Challenge for Both Inpatient & Outpatient Care The Goal: Get the Patient to Their Optimal Blood Volume & Don’t Over Treat Risks of Hypovolemia: Risks of Hypervolemia: • Tissue Hypoperfusion • Heart Failure Decompensation • Acute Kidney Injury • Accelerated Disease •
Slide 7: The Heated Debate at Bedside
“Should we try another treatment strategy?” The Heated Debate at Bedside Her hematocrit is very low. But she’s I think we need to find I think he’s still a bit wet, been getting lots of fluids. It’s not true another treatment he needs to be diuresed. anemia, it’s dilutional. strategy. COPYRIGHT © 20
Slide 8: Optimal Blood Volume is Central to Effective Heart Failure Management
Optimal Blood Volume is Central to Effective Heart Failure Management Other Volume Diagnostics are Inaccurate, Costly, and Invasive – Often Leading to Inferior Outcomes Single BVA-100 Single BVA-100 Bloo Blood Test COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 9: Who We Are
DAXOR BVA-100 WHO WE ARE
Slide 10: History of Innovation
History of Innovation INCREASING EVIDENCE GROWING TRACTION First RCT demonstrates Completed contracts from mortality benefit in ICU U.S. DoD for simpler, RESEARCH faster, POC portable (Yu 2011) Volume derangement analyzer – U.S. Air Force, shown clinically meaningful Heterogeneity of HF NIH/CAPCaT i
Slide 11: 98% Accurate: Leader in the New Measure of Care
Leader in the New Measure of Care Over 65,000+ Tests Performed Results FDA-Cleared Achievable Within 1 Hour 98% Accurate Inpatient Administered Direct Measurement at Point of + Care of Total Blood Volume, Outpatient Plasma, & Red Cell Volume Over 140+ Peer- Reviewed Studies Confirming Blood Volume S
Slide 12: Executive Summary: July 2022 – May 2023, Unaudited
Executive Summary: July 2022 – May 2023, Unaudited COMMERCIAL CLINICAL NEW PRODUCTS • 59.5% increase YOY in diagnostic kit sales • BVA selected for ‘Long Hauler ‘ COVID- • Completed ARMY/DoD contract for BVA • 20.5% increase in revenues from BVA 19 NIH Study portable combat care device for military
Slide 13: What We Do
DAXOR BVA-100 WHAT WE DO
Slide 14: Mission Vision
Mission Advance healthcare by enabling optimal fluid management with blood volume analysis. Vision Optimal blood volume for all. COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 15: The New Measure of Care
The New Measure of Care 98% Accurate Measurement Utilizes the Results of Total Blood, “Gold Standard” Achievable Plasma, & Red Methodology Within 1 Hour Cell Volume Available for Optimizes Drives Dramatic Inpatient & Treatments & Clinical Cost Outpatient Outcomes Savings Settings Computer Controlled
Slide 16: Over 65,000+ Tests Performed to Evaluate Blood Volume
Over 65,000+ Tests Performed to Evaluate Blood Volume COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 17: Innovation & Next Generation Products
DAXOR BVA-100 INNOVATION & NEXT GENERATION PRODUCTS
Slide 18: Game-Changing, Next-Generation BVA Submission in 2023
Game-Changing, Next-Generation BVA Submission in 2023 Simpler, quicker, portable blood volume analyzer including the development of novel fluorescent tracer expanding use into more clinical settings for more indications. Recipient of Over $2 Million in Military Contract Awards June 2020 November 201
Slide 19: Clinical Validation
DAXOR BVA-100 CLINICAL VALIDATION
Slide 20: Providing a Solution for the Most Common & Costly Conditions
Providing a Solution for the Most Common & Costly Conditions Blood volume derangements are common in a broad range of medical and surgical conditions including heart failure, critical care, sepsis, syncope, surgical blood loss, and ARDS. Heart Failure Critical Care Sepsis Syncope Surgical Blood Loss
Slide 21: Making a Difference in Multiple Medical Conditions
Making a Difference in Multiple Medical Conditions Patients With Critical Blood Volume Derangements in the U.S. Annually • Heart Failure: 6+M patients, 11M deaths, 1M annual hospitalizations • Critical Care/Sepsis: 8+M admissions annually • Broadening focus indications include combat casualty care,
Slide 22: Study Shows BVA Significantly Improves Heart Failure Treatment
Study Shows BVA Significantly Improves Heart Failure Treatment “The use of Daxor’s BVA-100 blood test in heart failure outcomes in this compelling study showed exceptional value by not only improving patient life span, but also at a cost which is significantly less than other commonly used therapies
Slide 23: BVA On Admission Results in 2.5 Days Reduction in Length of Stay
BVA On Admission Results in 2.5 Days Reduction in Length of Stay Average LOS = 2.0 Days Average LOS = 4.5 Days 56% Reduction in BVA Group Length of Stay Control Group National Average Days 0 1 2 3 4 5 6 7 6.5 Days Analysis of 71 Hospitalized Heat Failure Patients. Strobeck JE, et al., JACC-HF, 2018;
Slide 24: Excellent Value in Healthcare with Reimbursement
Excellent Value in Healthcare with Reimbursement Blood Volume-Guided Treatment Extremely Cost-Effective‡ Retrospective analysis in hospitalized heart failure patients | n = 245, Mixed HFpEF/HFrEF Well above 0.227 previously reported§ Far below the threshold of $50,000 ‡ Strobeck JE, Feldschuh J, Wil
Slide 25: BVA Significantly Improves Multiple Measures of Patient Outcomes in Critical Care
BVA Significantly Improves Multiple Measures of Patient Outcomes in Critical Care “Every clinician understands the importance of maintaining normal blood volume, but the problem is how to measure it. The blood volume analyzer will mitigate the heated debate at the bedside.” Dr. Mihae Yu †M. Yu, K. P
Slide 26: On-Going Trials 2022-2023
“Volume management is key to the successful management of heart failure and we On-Going Trials 2022-2023 are excited to study the utility of BVA in the setting of acute heart failure.” Duke University Medical Center Prospective randomized control First-of-it’s-kind multicenter BVA-100 study in hospi
Slide 27: Recent Published Data 2020-2023
Recent Published Data 2020-2023 COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 28: Business Model
DAXOR BVA-100 Business Model
Slide 29: Sales Model
Sales Model BVA-100 Device Price Volumex Single Use Kit Price Razor/Razorblade Model Acquisition: $85,000 $385 + S&H • Sale & lease of BVA-100 diagnostic systems Lease: $2,750 Per Month • Recurring sales of single BVA Reference Lab Services use test kits • Multi-million-dollar $300 contract awards &
Slide 30: Large, Sustainable, Serviceable Markets at Moderate Penetration Rates
Large, Sustainable, Serviceable Markets at Moderate Penetration Rates Addressable Market – Annual Recurring Revenue $2.3B Heart Failure $2,500 ~6M patients, 30% penetration $2,695 = 1.8M tests $2,000 $3.1B Critical Care, Sepsis $1,463 $1,500 ~8M patients, 20% penetration = 1.6M tests $1,000 $683 $61
Slide 31: Commercialization Channels
Commercialization Channels • Direct sales to major medical centers, hospitals & clinics for both inpatient & outpatient settings • Sales & clinical support team of 12 • International expansion with ISO 13485 certification • Military contract awards • Partnerships with Heart Failure Society of Americ
Slide 32: Patent, Research & Development Activity
Patent, Research & Development Activity 5 3 3 4 4 US Patents Awarded 20,000 SF 6 Research Facility Equipped with New Patents Filed New Patents State-of-the-Art Level 2020-2021 Anticipated for 2023 4 Clean Rooms Patents Pending plus numerous international patents (Europe, Japan, Canada, and the World
Slide 33: COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 34: Experience
Daxor is a MedAxiom Industry Partner Working Together to Achieve the Quadruple Aim Better Outcomes Quadruple Aim Lower Costs Improved Patient Experience Improved Clinical Experience COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 35: BVA Value Impact – the Quadruple Aim and More
BVA Value Impact – the Quadruple Aim and More Prevent Hospital Readmissions Improve Quality Metrics Individualize Treatment to Optimize Outcomes Reduce Length of Stay Inform Fluid Management Early Improve Mortality Save Hospital Resources COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 36: Growth Catalysts & Value Drivers
Growth Catalysts & Value Drivers Increasing distribution through programs with leading clinical & commercial alliances. Next-generation technology a leap in speed & ease of use. Additional clinical outcomes supplementing the clinical & economic benefits. Extensive R&D drives unique & expanding techn
Slide 37: Managing for Growth
Managing for Growth Institutionalizing adoption Expanding distribution Advancing diagnostic & Strong R&D with usage protocols & through direct sales force, therapeutic strategic with next generation device treatment guidance & 3rd party distributors alliances launch in 2023 Expanding studies Growing
Slide 38: Key Metrics
Key Metrics 1940 Act Reporting Company | Publicly Traded Since 1971 Stock Symbol: DXR Exchange: Nasdaq Recent Price: $11.33 (a/o 05/02/23) 52 Week Range: $7.81 to $14.55 Market Cap: $45.6M (a/o 05/02/23) Shares Outstanding: 4.32M Free Float: 1.6M Insider Ownership: 63.7% Net Assets: $27.4M (a/o 4/30
Slide 39: Highlights
Highlights Diagnostic division revenue growth 20.5% FY 2022 Over 65,000+ tests performed Broad and deep IP portfolio with patented technology Over 140+ peer-reviewed published studies Clean capital structure, strong balance sheet, no warrants, small float Provides individualized treatment, reduces m
Slide 40: Senior Leadership
Senior Leadership Michael Feldschuh Jonathan Feldschuh Robert Michel, CPA, MBA President and Chief Scientific Officer Chief Financial Officer Chief Executive Officer Harvard University Villanova University Columbia University St John’s University, MBA Kathryn A. Kornafel, Jean Oertel Linda Cooper MT
Slide 41: Key Contacts
Key Contacts Investor Relations Transfer Agent Bret Shapiro Continental Stock Transfer CORE IR 1 State Street, 30 Floor, NY, NY 10004 377 Oak Street, Garden City, NY 11530 212-509-4000 | cstmail@continentalstock.com 516-222-2560 | brets@coreir.com www.continentalstock.com www.coreir.com Auditors Cor
Slide 42: Daxor.com
107 Meco Lane, Oak Ridge, TN 37830 865-425-0555 | info@daxor.com Daxor.com